Skip to main content
Order CJC-1295

A curated front page of the CJC-1295 research — the GHRH-analog pharmacology, the DAC-vs-no-DAC half-life split, and the finding that growth-hormone pulsatility survives continuous stimulation, every study laid out as its own card.

Read the original study papers

Which CJC-1295 papers support the findings

The compound studied in these papers changes growth-hormone release. The papers describe what researchers measured and in whom. You'll find numbered links for checking the findings and their limits.

Go back to the human findingsGo back to the opening page

What the numbered CJC-1295 papers tested

2006 research by Teichman measured lasting hormone rises in people [3]. Another 2006 paper, by Ionescu/Frohman, checked the timing of hormone spurts [1]. You can follow each number to the linked paper below. Think of the number as a page number in your newspaper index.

2005 work by Jette tested linking albumin, a protein in blood, with the compound [2]. Alba's 2006 study tested mice's growth when they lacked the hormone starting release [4]. Those mouse findings differ from the hormone tests in people. Neither kind of result automatically establishes a treatment benefit for you.

2009 research by Sackmann-Sala found changes in men's blood proteins [5]. The 2025 Nature Reviews Endocrinology review examined the broader group of related compounds [14]. Other papers tested hormone-releasing substances given together or timing of hormone release. Your linked papers let you see which substance each experiment concerned.

Most papers give you published studies or expert reviews of research. One identified CJC-1295 in a seized, unidentified drug mixture [6]. Detection in that mixture doesn't show whether using the compound is safe. You need evidence about health to answer a health claim.

Each CJC-1295 entry links to a paper or description of the research. The numbers beside findings lead you to those entries. You're able to read what was tested beyond someone's summary of the results. These papers don't supply the missing long-term human safety trials.

  1. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration on GH release. J Clin Endocrinol Metab. 1996;81(3). ↗
  8. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009. ↗
  9. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced GH secretion. Endocrinology. 2002. ↗
  10. Differential pulsatile secretagogue control of GH secretion in healthy men. Am J Physiol Regul Integr Comp Physiol. 2013. ↗
  11. Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing. Oncotarget. 2016. ↗
  12. GHRH expression plasmid improves osteoporosis and skin damage in aged mice. Growth Horm IGF Res. 2021. ↗
  13. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  14. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  15. Neuroendocrine circuit for sleep-dependent growth hormone release. Cell. 2025. ↗
  16. (2026 peptide therapy safety review). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
  17. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗
  18. (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
  19. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  20. ConjuChem Inc. (trial sponsor). A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov. 2006. ↗
  21. Reference summary. Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. ↗
  22. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗